Lynn is a biotech entrepreneur and the Founder and CEO of STALICLA, a clinical stage first-in-class biotech company using Artificial Intelligence to identify specific subgroups of patients and create precision medicine for the treatment of neurodevel opmental disorders (including Autism Spectrum Disorder, Schizophrenia, Dyspraxia, ID etc…).
Driven by her lifelong involvement with the autism community, Lynn has instituted a paradigm shift in the neurodevel opmental disorder (NDD) drug discovery space by pioneering the creation of the first NDD specific precision medicine discovery platform.
To date, Lynn has assembled a 22 FTE world-class cross functional team of drug developers, clinicians and data scientists in STALICLA’s Geneva and Barcelona Drug Development and Discovery and data science units. She has also fostered the creation as a unique collaborative network of 18 academic leading research centers, hospitals and CROs in t he US and Europe.
In just ove r 3,5 years since inception, she has led STALICLA in expediting and lowering drug development risk for a first biolog ically-validated sub-group of patients with Autism. The corresponding drug candidate -STP1 - received FDA IND cleara nce to enter clinical trials in September 2020. STALICLA is also currently running several observational trials in th e US and Europe.
In parallel, Lynn has raised CHF 23 M ( $ 23) in aggregate to support STALICLA’s development.
Lynn has authored and co-authored 7 patents and is the recipient of a brain Foundation award for outstanding contributi on to the advancement of treatments in Neurodevelopmental disorders.
Lynn hol ds a Masters degree in economic history and political science from ICP Paris, a Masters degree in corporate communi cation from NEOMA Business School and a post graduate Masters degree in clinical trials and drug developm ent from the Faculty of medicine of the University of Geneva. To date, Lynn has assembled a 17 FTE world-class cross functional team of drug developers, clinicians and data scientists in STALICLA’s Geneva (STALICLA Drug Development) and Barcelona (STALICLA R&D) units as well as a unique collaborative network of 18 academic leading research centers & hospitals and CROs in the US.
In parallel, Lynn has raised CHF 10M in Series A and has just secured an additional CHF 8M to support STALICLA’s development.
Driven by her lifelong involvement with the autism community, Lynn has instituted a paradigm shift in the neurodevel opmental disorder (NDD) drug discovery space by pioneering the creation of the first NDD specific precision medicine discovery platform.
To date, Lynn has assembled a 22 FTE world-class cross functional team of drug developers, clinicians and data scientists in STALICLA’s Geneva and Barcelona Drug Development and Discovery and data science units. She has also fostered the creation as a unique collaborative network of 18 academic leading research centers, hospitals and CROs in t he US and Europe.
In just ove r 3,5 years since inception, she has led STALICLA in expediting and lowering drug development risk for a first biolog ically-validated sub-group of patients with Autism. The corresponding drug candidate -STP1 - received FDA IND cleara nce to enter clinical trials in September 2020. STALICLA is also currently running several observational trials in th e US and Europe.
In parallel, Lynn has raised CHF 23 M ( $ 23) in aggregate to support STALICLA’s development.
Lynn has authored and co-authored 7 patents and is the recipient of a brain Foundation award for outstanding contributi on to the advancement of treatments in Neurodevelopmental disorders.
Lynn hol ds a Masters degree in economic history and political science from ICP Paris, a Masters degree in corporate communi cation from NEOMA Business School and a post graduate Masters degree in clinical trials and drug developm ent from the Faculty of medicine of the University of Geneva. To date, Lynn has assembled a 17 FTE world-class cross functional team of drug developers, clinicians and data scientists in STALICLA’s Geneva (STALICLA Drug Development) and Barcelona (STALICLA R&D) units as well as a unique collaborative network of 18 academic leading research centers & hospitals and CROs in the US.
In parallel, Lynn has raised CHF 10M in Series A and has just secured an additional CHF 8M to support STALICLA’s development.
Speaking In
[Available On-Demand]
STALICLA is a Swiss clinical stage biotech company on a unique mission to identify, develop and…
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
